Molecules with extended half-lives, compositions and uses...

Details Molecules with extended half-lives, compositions and uses... Molecules with extended half-lives, compositions and uses...

2006-08-01

2006-08-01

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C530S387100, C530S387700, C530S387900, C435S810000

Reexamination Certificate

active

07083784

ABSTRACT:
The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

REFERENCES:
patent: 4703039 (1987-10-01), Hawiger et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5869046 (1999-02-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6737056 (2004-05-01), Presta
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2003/0190311 (2003-10-01), Dall'Acqua et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 0 368 684 (1990-05-01), None
patent: 0 327 378 (1996-12-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/43316 (1997-11-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 01/58957 (2001-08-01), None
patent: WO 03/054213 (2003-07-01), None
patent: WO 04/016750 (2004-02-01), None
patent: WO 04/029207 (2004-04-01), None
patent: WO 04/035752 (2004-04-01), None
U.S. Appl. No. 09/724,396, filed Nov. 28, 2000, Young et al.
U.S. Appl. No. 09/724,531, filed Nov. 28, 2000, Young et al.
U.S. Appl. No. 09/996,265, filed Nov. 28, 2001, Young et al.
U.S. Appl. No. 09/996,288, filed Nov. 28, 2001, Young et al.
Borvak et al., 1998,Intern. Immunol.10(9):1289-1298.
Cianga et al., 1999,Eur. J. Immunol.29(8):2515-2523.
Fields et al., 1996,Immunotechnology2(4):270.
Firan et al., 2001,Intern. Immunol.13:993-1002.
Ghetie et al., 2000,Annual Rev. Immunol.18:739-766.
Ghetie et al., 1996,Eur. J. Immunol.26:690-696.
Ghetie et al., 1997,Nature Biotech.15(7):637-640.
Ho et al., 1989,Gene15:51-59.
Israel et al., 1996,Immunol.89:573-578.
Johnson et al., 1997,J. Infectious Disease176:1215-1224.
Junghans, 1997,Immunologic Research16(1):29-57.
Junghans et al., 1996,Proc. Natl. Acad. Sci. USA93:5512-5516.
Junghans, 1997,Blood90(10):3815-3818.
Junghans, 1997,Trends in Biotechnology5(15):155.
Kabat et al., 1991, Sequences of Proteins of Immunological Interest, U.S. Public Health Service, National Institutes of Health.
Kim et al., 1994,Scandinavian J. Immunol.40(4)457-465.
Kim et al., 1995,Mol. Immunol.32(7):467-475.
Kim et al., 1994,Eur. J. Immunol.24:542-548.
Kim et al., 1994,Eur. J. Immunol.24:2429-2439.
Kim et al., 1994,FASEB J.8:pA467.
Kim et al., 1994,9th International Congress of Immunol., p. 469.
Kunkel et al., 1987,Methods Enzymol.154:367-382.
Li et al., 1997,J. Mol. Biol.269(3):385-394.
Martin and Bjorkman, 1999,Biochemistry38:12639-12647.
Medesan et al., 1996,Eur. J. Immunol.26:2533-2536.
Medesan et al., 1997,J. Immunol.158:2211-2217.
Medesan et al., 1998,Eur. J. Immunol.28(7):2092-2100.
Popov et al., 1996,Mol. Immunol.33:493-502.
Popov et al., 1996,Mol. Immunol.33:521-530.
Sanger et al., 1977,Proc. Natl. Acad. Sci. USA74:5463-5467.
Schuck, et al., 1999,Mol. Immunol.36:1117-1125.
Shields et al., 2001,J. Biol. Chem.276:6591-6604.
Story et al., 1994,J. Exp. Med.180:2377-2381.
Thatte et al., 1999,J. Exp. Med.189(3):509-520.
van der Merwe et al., 1993,EMBO J.12:4945-4594.
van der Merwe et al., 1994,Biochemistry33:10149-10160.
Vaughn and Bjorkman, 1997,Biochemistry, 36:9374-9380.
Ward and Qadri, 1997,Current Opinion Immunol.9(1)97-106.
Ward and Ghetie, 1995,Ther. Immunol.2:77-94.
West and Bjorkman, 2000,Biochemistry39:9698-9708.
Ahouse et al. Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol. Dec. 1, 1993; 151(11):6076-88.
Burmeister et al. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature. Nov. 24, 1994;372(6504):336-43.
Burmeister et al. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. Nov. 24, 1994;372(6504):379-83.
Chintalacharuvu et al. Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol. Oct. 2001;101(1):21-31.
Cianga et al. Identification and function of neonatal Fc receptor in mammary gland of lactating mice. Eur J Immunol. Aug. 1999;29(8):2515-23.
Dickinson et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. Oct. 1999;104(7):903-11.
Ghetie et al. Multiple roles for the major histocompatibility complex class I—related receptor FcRn. Annu Rev Immunol. 2000;18:739-66. Review.
Kristoffersen et al. Co-localization of the neonatal Fc gamma receptor and IgG in human placental term syncytiotrophoblasts. Eur J Immunol. Jul. 1996;26(7):1668-71.
Martin et al. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry. Sep. 28, 1999;38(39):12639-47.
Raghavan et al. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity. Jul. 1994;1(4):303-15.
Raghavan et al. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry. Nov. 14, 1995;34(45):14649-57.
Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol. Nov. 1976;71(2):666-9.
Sanchez et al. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry. Jul. 20, 1999;38(29):9471-6.
Simister et al. An Fc receptor structurally related to MHC class I antigens. Nature. Jan. 12, 1989;337(6203):184-7.
Vaughn et al. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry. Aug. 5, 1997;36(31):9374-80.
Vaughn et al. Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol. Dec. 12, 1997;274(4):597-607.
Wallace et al. Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine. Biochem J. Apr. 15, 1980;188(1):9-16.
Kim et al., 1999, “Mapping the Site on Human IgG for Binding of the MHC Class I-Related Receptor, FcRn,” Eur. J. Immunol., 29:2819-2825.

Affiliated with

Also associated with

Rating

Molecules with extended half-lives, compositions and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecules with extended half-lives, compositions and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecules with extended half-lives, compositions and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3656757